Latest news with #MattBarnes
Associated Press
02-06-2025
- Business
- Associated Press
Nxera Pharma Achieves Development Milestone in Collaboration with Eli Lilly Targeting Metabolic Diseases
Tokyo, Japan and Cambridge, UK, 2 June 2025 – Nxera Pharma Co., Ltd. ('Nxera' or 'the Company'; TSE 4565) today announces that it has achieved a development milestone under its multi-target collaboration and license agreement with Eli Lilly and Company ('Lilly') targeting diabetes and metabolic diseases, resulting in a payment to Nxera. The payment amount is undisclosed under the agreement with Lilly. However, Nxera makes this announcement in accordance with the timely disclosure requirements as the achievement of the milestone represents significant progress in research and development for Nxera. Nxera expects to receive the milestone payment in the third quarter of the fiscal year ending December 2025. Nxera and Lilly entered the multi-target collaboration in 2022 to leverage Nxera's GPCR-focused structure-based drug design capabilities and Lilly's extensive development, commercialization and therapeutic area expertise. The achievement of this development milestone validates the use of Nxera's NxWave™ platform to successfully identify small molecule binders to GPCR targets and to solve the structure of the receptor in the presence of the small molecule, thus revealing its binding site. Lilly will now be responsible for further development and commercialization. Under the terms of the agreement, Nxera is eligible to receive development and commercial milestones totalling up to US$694 million, plus tiered royalties on global sales. Dr. Matt Barnes, CSO and President of Nxera Pharma UK, commented: 'We're excited to have achieved this important milestone in this collaboration with Lilly, which marks a significant step towards developing novel treatments in these important areas of unmet need across diabetes and metabolic diseases. Our proprietary NxWave™ platform has continuously produced novel molecules for previously intractable targets, and we look forward to seeing further developments from this productive collaboration with Lilly.' –END– About Nxera Pharma Nxera Pharma is a technology powered biopharma company in pursuit of new specialty medicines to improve the lives of patients with unmet needs in Japan and globally. We have built an agile, new-generation commercial business in Japan to develop and commercialize innovative medicines, including several launched products, to address this high value, large and growing market and those in the broader APAC region. Behind that, and powered by our unique NxWave™ discovery platform, we are advancing an extensive pipeline of over 30 active programs from discovery through to late clinical stage internally and in partnership with leading pharma and biotech companies. This pipeline of potentially first- and best-in-class candidates is focused on addressing major unmet needs in some of the fastest-growing areas of medicine across neurology/neuropsychiatry, metabolic diseases and immunology and inflammation. Nxera employs approximately 400 talented people at key locations in Tokyo and Osaka (Japan), London and Cambridge (UK), Basel (Switzerland) and Seoul (South Korea) and is listed on the Tokyo Stock Exchange (ticker: 4565). For more information, please visit LinkedIn: @NxeraPharma | X: @NxeraPharma | YouTube: @NxeraPharma Enquiries: Nxera – Media and Investor Relations Shinya Tsuzuki, VP, Head of Investor Relations Shinichiro Nishishita, VP Investor Relations, Head of Regulatory Disclosures Maya Bennison, Communications Manager +81 (0)3 5962 5718 | +44 (0)1223 949390 |[email protected] MEDiSTRAVA (for International Media) Mark Swallow, Frazer Hall, Erica Hollingsworth +44 (0)203 928 6900 | [email protected] Forward-looking statements This press release contains forward-looking statements, including statements about the discovery, development, and commercialization of products. Various risks may cause Nxera Pharma Group's actual results to differ materially from those expressed or implied by the forward looking statements, including: adverse results in clinical development programs; failure to obtain patent protection for inventions; commercial limitations imposed by patents owned or controlled by third parties; dependence upon strategic alliance partners to develop and commercialize products and services; difficulties or delays in obtaining regulatory approvals to market products and services resulting from development efforts; the requirement for substantial funding to conduct research and development and to expand commercialization activities; and product initiatives by competitors. As a result of these factors, prospective investors are cautioned not to rely on any forward-looking statements. We disclaim any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Yahoo
01-06-2025
- Business
- Yahoo
Nxera Pharma Achieves Development Milestone in Collaboration with Eli Lilly Targeting Metabolic Diseases
Tokyo, Japan and Cambridge, UK, 2 June 2025 – Nxera Pharma Co., Ltd. ('Nxera' or 'the Company'; TSE 4565) today announces that it has achieved a development milestone under its multi-target collaboration and license agreement with Eli Lilly and Company ('Lilly') targeting diabetes and metabolic diseases, resulting in a payment to Nxera. The payment amount is undisclosed under the agreement with Lilly. However, Nxera makes this announcement in accordance with the timely disclosure requirements as the achievement of the milestone represents significant progress in research and development for Nxera. Nxera expects to receive the milestone payment in the third quarter of the fiscal year ending December 2025. Nxera and Lilly entered the multi-target collaboration in 2022 to leverage Nxera's GPCR-focused structure-based drug design capabilities and Lilly's extensive development, commercialization and therapeutic area expertise. The achievement of this development milestone validates the use of Nxera's NxWave™ platform to successfully identify small molecule binders to GPCR targets and to solve the structure of the receptor in the presence of the small molecule, thus revealing its binding site. Lilly will now be responsible for further development and commercialization. Under the terms of the agreement, Nxera is eligible to receive development and commercial milestones totalling up to US$694 million, plus tiered royalties on global sales. Dr. Matt Barnes, CSO and President of Nxera Pharma UK, commented: 'We're excited to have achieved this important milestone in this collaboration with Lilly, which marks a significant step towards developing novel treatments in these important areas of unmet need across diabetes and metabolic diseases. Our proprietary NxWave™ platform has continuously produced novel molecules for previously intractable targets, and we look forward to seeing further developments from this productive collaboration with Lilly.' –END– About Nxera PharmaNxera Pharma is a technology powered biopharma company in pursuit of new specialty medicines to improve the lives of patients with unmet needs in Japan and globally. We have built an agile, new-generation commercial business in Japan to develop and commercialize innovative medicines, including several launched products, to address this high value, large and growing market and those in the broader APAC region. Behind that, and powered by our unique NxWave™ discovery platform, we are advancing an extensive pipeline of over 30 active programs from discovery through to late clinical stage internally and in partnership with leading pharma and biotech companies. This pipeline of potentially first- and best-in-class candidates is focused on addressing major unmet needs in some of the fastest-growing areas of medicine across neurology/neuropsychiatry, metabolic diseases and immunology and inflammation. Nxera employs approximately 400 talented people at key locations in Tokyo and Osaka (Japan), London and Cambridge (UK), Basel (Switzerland) and Seoul (South Korea) and is listed on the Tokyo Stock Exchange (ticker: 4565). For more information, please visit LinkedIn: @NxeraPharma | X: @NxeraPharma | YouTube: @NxeraPharma Enquiries: Nxera – Media and Investor RelationsShinya Tsuzuki, VP, Head of Investor RelationsShinichiro Nishishita, VP Investor Relations, Head of Regulatory DisclosuresMaya Bennison, Communications Manager+81 (0)3 5962 5718 | +44 (0)1223 949390 |IR@ MEDiSTRAVA (for International Media)Mark Swallow, Frazer Hall, Erica Hollingsworth+44 (0)203 928 6900 | Nxera@ Forward-looking statementsThis press release contains forward-looking statements, including statements about the discovery, development, and commercialization of products. Various risks may cause Nxera Pharma Group's actual results to differ materially from those expressed or implied by the forward looking statements, including: adverse results in clinical development programs; failure to obtain patent protection for inventions; commercial limitations imposed by patents owned or controlled by third parties; dependence upon strategic alliance partners to develop and commercialize products and services; difficulties or delays in obtaining regulatory approvals to market products and services resulting from development efforts; the requirement for substantial funding to conduct research and development and to expand commercialization activities; and product initiatives by competitors. As a result of these factors, prospective investors are cautioned not to rely on any forward-looking statements. We disclaim any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
28-05-2025
- General
- Yahoo
NBC4 Sponsors 2025 ACEs, PACEs and Addiction Summit: ‘From Resilience to Action'
COLUMBUS, Ohio (WCMH) — NBC4 is proud to sponsor the 2025 ACEs, PACEs and Addiction Summit, presented by Franklin County Public Health, on Monday, July 21, 2025, at the Quest Conference Center in Westerville, Ohio. This impactful, community-focused event addresses Adverse Childhood Experiences (ACEs), promotes Protective and Compensatory Experiences (PACEs), and inspires proactive approaches to combat addiction and support healing across Franklin County. This year's theme, 'From Resilience to Action: Transforming ACEs Outcomes in Franklin County,' will guide a full day of education, collaboration, and empowerment among healthcare professionals, educators, social workers, community leaders, and advocates. NBC4 Today anchor Matt Barnes will serve as emcee for the event, to this vital community conversation. Date: Monday, July 21, 2025Time: 8 a.m. to 3:30 Quest Conference Center, 9200 Worthington Road, Westerville, Ohio 43082 Admission: Free (Registration required, click here to register) Attendees will hear from nationally recognized speakers, participate in expert-led sessions, and connect with local resources focused on building trauma-informed communities and systems of care. NBC4's sponsorship underscores its ongoing commitment to public health and advocacy work across Central Ohio. To learn more, visit the official summit page. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Time of India
21-05-2025
- Entertainment
- Time of India
Why do older women appeal to NBA players? Matt Barnes has a perfect answer to the burning question
Why do older women appeal to NBA players? Matt Barnes has a perfect answer to the burning question (Image Source: Getty Images) Something unexpected happened on a quiet April day in 2025. During a normal episode of All The Smoke Podcast , former NBA star Matt Barnes said something, causing many listeners to break down. It was not about basketball, statistics or wardrobes. There was something personal. Something raw, and it was about love. Matt Barnes sat faced with guest writer Jason Wilson, and opened like never before. And what he shared about NBA players and their dating choices, especially with older women, posed real conversations far beyond the court. Something unexpected happened on a quiet April day in 2025. During a normal episode of All The Smoke Podcast, former NBA star Matt Barnes said something, causing many listeners to break down. It was not about basketball, statistics or wardrobes. There was something personal. Something raw, and it was about love. Matt Barnes sat faced with guest writer Jason Wilson, and opened like never before. And what he shared about NBA players and their dating choices, especially with older women, posed real conversations far beyond the court. Matt Barnes reveals why NBA players date older women Matt Barnes, a former NBA player who won a championship in 2017 with the Golden State Warriors , recently spoke about dating habits among players in the NBA. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Giao dịch vàng với sàn môi giới tin cậy IC Markets Đăng ký Undo He stated that older women can bring a sense of security and feel like home for younger partners. He stressed that being a successful athlete demands a partner who is mature and supportive. During the podcast, Matt Barnes stated, "Older women have been through life. They understand the pressure we are facing and offer a level of support that is difficult to find elsewhere." He emphasised that relationships with older women may be more grounded, which is beneficial for athletes who work on their careers. Matt Barnes Reveals Why NBA Players Dating Older Women. This perspective sheds light on the personal choices of athletes and the factors that affect their relationships. The full discussion can be found at The All Smoke Podcast episode with Jason Wilson. Matt Barnes shared his personal experiences of his marriage Matt Barnes was born on March 9, 1980, in Santa Clara, California, and had a diversified education with an African-American father and an Italian mother. He faced many challenges, including drug exposure, violence and the loss of his mother at 27. In April 2025, Matt Barnes shared his emotional departure on the podcast. He revealed that it's been 30 years since he has cried and said, "I'm starting to feel it now. I feel like I'm almost pouring from an empty cup." This emotional detachment, he admitted, contributed to the end of the relationship with groom Anansa Sims. Anansa Sims, the daughter of Beverly Johnson's model, began dating Matt Barnes in 2018 and was involved in December 2022. They have 2 children together. Sims also has 3 children from a previous relationship. At the beginning of 2025, Sims accused Matt Barnes of infidelity and criticised his lack of emotional support for their mixed family. She urged him to seek therapy and build a stronger spiritual basis. Also read: Former NBA star blames Boston Celtics' loss on Jayson Tatum's torn Achilles, predicts Indiana Pacers will defeat New York Knicks Get IPL 2025 match schedules , squads , points table , and live scores for CSK , MI , RCB , KKR , SRH , LSG , DC , GT , PBKS , and RR . Check the latest IPL Orange Cap and Purple Cap standings.
Associated Press
10-04-2025
- Entertainment
- Associated Press
Rogue Aviation Unveils the Ultimate Pilot Experience in Southern California
Step into the cockpit and take control of a helicopter, soaring over the stunning landscapes of Southern California and guided by an expert pilot 'This isn't a simulator or a passive ride—you are in the pilot's seat. It's a thrilling, safe, fully guided flight that gives you a taste of what it's like to truly fly.' — Matt Barnes, Rogue Aviation's owner and director of education LONG BEACH, CA, UNITED STATES, April 10, 2025 / / -- Rogue Aviation has launched a new hands-on flight adventure that gives everyday people the chance to pilot a helicopter under the guidance of a certified instructor. The Rogue Aviation Pilot Experience lets participants take control of a helicopter and fly over some of Southern California's most iconic coastlines and cityscapes. Launched this month from the company's Long Beach hub, the Pilot Experience invites adventure-seekers and aspiring aviators to climb into the cockpit, grab the controls, and soar over legendary sites like the Hollywood sign, downtown Los Angeles, the Queen Mary and the pristine Orange County coastline. 'This isn't a simulator or a passive ride—you are in the pilot's seat,' said Matt Barnes, Rogue Aviation's owner and director of education. 'It's a thrilling, safe, fully guided flight that gives you a taste of what it's like to truly fly.' This day-as-a-pilot experience includes: • A safety briefing and pre-flight inspection of your aircraft • A private hangar tour and photo ops with your pilot • A scenic 60- or 90-minute flight, with a chance to control the helicopter yourself • The Hover Challenge—try to hover the aircraft and earn epic bragging rights • Flight time officially logged in your own pilot logbook Pricing begins at $897 per person, with options to upgrade aircraft, add guests, capture the moment with GoPro footage, or enjoy lunch from local vendors. Participants also receive exclusive Rogue Aviation Pilot merchandise, including a flight certificate, a pilot wings pin, and a badge of honor—literally. Whether for a birthday, a bucket list item, or the start of something bigger, the Rogue Aviation Pilot Experience is now booking for individuals and groups, with customizable packages available. About Rogue Aviation Rogue Aviation is a premier helicopter services provider in Southern California, offering unique aerial experiences, private charters, and flight training. Known for its state-of-the-art aircraft and expert pilots, Rogue Aviation allows guests to explore Southern California from the skies. Whether through scenic tours or the hands-on Pilot Experience, Rogue Aviation combines adventure, education, and safety for an unforgettable flying experience. Learn more at Cara Stewart WunderMarx Inc. X LinkedIn Instagram TikTok Legal Disclaimer:
